Can Carafate and Reglan Be Taken Together?
Yes, Carafate (sucralfate) and Reglan (metoclopramide) can be taken together, but they must be administered separately with appropriate timing intervals to avoid drug interaction.
Key Administration Requirement
The critical issue is timing, not compatibility. According to the FDA drug label for Carafate, sucralfate can bind to other medications in the gastrointestinal tract and reduce their absorption 1. The solution is straightforward: administer metoclopramide at least 2 hours before sucralfate 1.
Why This Matters
- Sucralfate's mechanism: This aluminum hydroxide complex forms a protective barrier in the GI tract and remains unabsorbed, residing there for considerable time 2
- Non-systemic interaction: The binding occurs physically in the stomach/intestine, not through metabolic pathways 1
- Documented solution: Studies specifically demonstrate that dosing the concomitant medication 2 hours before sucralfate eliminates the interaction 1
Clinical Context Where Both Are Used
These medications serve complementary purposes and are commonly used together in critically ill patients:
- Metoclopramide: Prokinetic agent that enhances gastric emptying and provides antiemetic effects 3, 4
- Sucralfate: Forms mucosal barrier for stress ulcer prophylaxis, though evidence for this indication is mixed 5, 6
In pregnancy-related nausea/vomiting, metoclopramide is recommended as safe and effective 3, 4, while sucralfate might be used for concurrent GI protection if needed.
Practical Administration Protocol
- Give Reglan (metoclopramide) first
- Wait minimum 2 hours
- Then give Carafate (sucralfate)
- Monitor for therapeutic effects of both medications
Important Caveats
- Metoclopramide warnings: Risk of tardive dyskinesia increases with duration >12 weeks and higher doses; extrapyramidal effects possible 7, 3
- Sucralfate considerations: Contains aluminum; use caution in renal impairment 1
- No evidence against combination: There is no contraindication to using both drugs—only the need for proper spacing 1
The FDA label explicitly states that when alterations in bioavailability are critical, "patients should be monitored appropriately" and dosing should be separated 1. This is a manageable interaction in clinical practice 2.